Nephrotoxicity of cyclosporin A in hereditary hypertriglyceridemic rats.
It has been suggested that cyclosporin A (CsA) nephrotoxicity can be reduced by the concomitant administration of omega-3 fatty acids or vitamin E. The present study was designed to establish whether the effect of the above substances can also be demonstrated in rats with hereditary hypertriglyceridemia (HTG) whose sensitivity to the nephrotoxic effect is greater than in control AVN rats. CsA administration at a dose of 10 mg/kg/day to HTG rats resulted in a significant rise (p<0.001) in serum levels of creatinine (from 66.0+/-7.6 to 108.4+/-11.6 micromol/l) and urea (from 8.3+/-0.7 to 22.3+/-18 mmol/l) which was not found in AVN rats. The baseline values of systolic blood pressure (SBP) were significantly higher in HTG rats. However, in both strains CsA administration was associated with a similar SBP increase which was not prevented by omega-3 fatty acids (EPAX) or vitamin E administration. Concomitant administration of CsA with EPAX at a dose of 600 mg/kg b.w./day in HTG rats prevented the rise in the serum levels of creatinine (65.4+/-14.7 micromol/l) and reduced the increase in the serum urea levels (11.9+/-7.6 mmol/l). Concomitant administration of CsA and vitamin E (at a dose of 25 mg/kg/day) also reduced the increase (p<0.05) in the serum levels of creatinine (70.7+/-14.3 micromol/l) and urea (9.8+/-3.4 mmol/l) compared to the effects elicited by the administration of CsA alone (p<0.05). Administration of CsA alone or in combination with EPAX or vitamin E did not have a marked effect on diuresis, proteinuria, urinary osmolality, urinary excretion of urea, creatinine and potassium. Under all experimental conditions, the rate of urinary excretion of sodium in HTG rats was significantly lower (p<0.01) than in AVN rats. The results obtained support the assumption that omega-3 fatty acids and vitamin E at the doses used reduce CsA nephrotoxicity in rats with hereditary hypertriglyceridemia whose sensitivity to the nephrotoxic effect of CsA is significantly higher than in AVN rats.
Bohdanecká
M
M
Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Schück
O
O
Chadimová
M
M
Sedivý
J
J
Glagolicová
A
A
Skibová
J
J
Kunes
J
J
Dobesová
Z
Z
Stuchlík
M
M
Veselá
J
J
Kazdová
L
L
D000818:Animals; D003401:Creatine / Q000652:urine; D016572:Cyclosporine / Q000633:toxicity*; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology*; D015228:Hypertriglyceridemia / Q000188:drug therapy / Q000235:genetics*; D007166:Immunosuppressive Agents / Q000633:toxicity*; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D008297:Male; D009994:Osmolar Concentration; D011188:Potassium / Q000652:urine; D011507:Proteinuria / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D051381:Rats; D011922:Rats, Mutant Strains; D017208:Rats, Wistar; D012964:Sodium / Q000652:urine; D014280:Triglycerides / Q000097:blood; D014508:Urea / Q000652:urine; D014810:Vitamin E / Q000494:pharmacology*
D015525:Fatty Acids, Omega-3; D007166:Immunosuppressive Agents; D014280:Triglycerides; D014810:Vitamin E; D016572:Cyclosporine; D014508:Urea; D012964:Sodium; D003401:Creatine; D011188:Potassium